Circulating antibodies to p16 protein‑derived peptides in breast cancer

Chen,Cairen; Huang,Yile; Zhang,Cong; Liu,Tong; Zheng,He; Wan,Shuli; Sun,Shilong; Meng,Qingyong; Chen,Yubing; Wei,Jun

doi:10.3892/mco.2015.485

Circulating antibodies to p16 protein‑derived peptides in breast cancer

Authors:
- Cairen Chen
- Yile Huang
- Cong Zhang
- Tong Liu
- He Zheng
- Shuli Wan
- Shilong Sun
- Qingyong Meng
- Yubing Chen
- Jun Wei
View Affiliations

Affiliations: School of Clinical Laboratory Science, Guangdong Medical College, Dongguan 523808, P.R. China, School of Public Health and MH Radiobiology Research Unit, Jilin University, Changchun 130118, P.R. China, Department of Breast Surgery, Third Affiliated Hospital of Harbin Medical University, Harbin 150081, P.R. China, Department of Radiotherapy, Second Hospital of Jilin University, Changchun 130041, P.R. China, Division of Health Research, University of the Highlands and Islands, Centre for Health Science, Inverness IV2 3JH, UK
Published online on: January 14, 2015 https://doi.org/10.3892/mco.2015.485
Pages: 591-594

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Overexpression of the p16 protein has been reported in breast cancer and may trigger the secretion of antibodies against itself. Circulating anti‑p16 antibodies that were detected with a recombinant protein have been reported in breast cancer. The present study was designed to determine whether the levels of circulating IgG antibody to p16 protein‑derived linear antigens are altered in breast cancer. An enzyme‑linked immunosorbent assay (ELISA) was developed in‑house to determine circulating IgG against peptide antigens derived from the p16 protein in 152 female breast cancer patients and 160 healthy female subjects. The Student's t‑test revealed that breast cancer patients exhibited significantly higher levels of anti‑p16 IgG antibody compared to control subjects (t=2.02, P=0.045). In addition, ductal cancer appeared to be the main type contributing to the increased levels of circulating anti‑p16 antibodies (t=2.08, P=0.038). Of all four stages of breast cancer, stage I was associated with the highest levels of IgG antibody (t=2.02, P=0.045) and receiver operating characteristic (ROC) analysis demonstrated that the area under the ROC curve was 0.74 (95% confidence interval: 0.65‑083) and that the sensitivity against a specificity of 90% was 30.3%. Therefore, the levels of circulating IgG antibody to the p16 protein may be a potential biomarker for early diagnosis of breast cancer.

View Figures

View References

1	Reuschenbach M, von Knebel, Doeberitz M and Wentzensen N: A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother. 58:1535–1544. 2009. View Article : Google Scholar : PubMed/NCBI
2	Tan HT, Low J, Lim SG and Chung MC: Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 276:6880–6904. 2009. View Article : Google Scholar : PubMed/NCBI
3	Kobold S, Lütkens T, Cao Y, Bokemeyer C and Atanackovic D: Autoantibodies against tumor-related antigens: incidence and biologic significance. Hum Immunol. 71:643–651. 2010. View Article : Google Scholar : PubMed/NCBI
4	Liu W, Peng B, Lu Y, Xu W, Qian W and Zhang JY: Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev. 10:331–335. 2011. View Article : Google Scholar : PubMed/NCBI
5	Ludwig N, Keller A, Leidinger P, et al: Is there a general autoantibody signature for cancer? Eur J Cancer. 48:2451–2461. 2012. View Article : Google Scholar : PubMed/NCBI
6	Xu YW, Peng YH, Chen B, et al: Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol. 109:36–45. 2014. View Article : Google Scholar : PubMed/NCBI
7	Lam S, Boyle P, Healey GF, et al: EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 4:1126–1134. 2011. View Article : Google Scholar : PubMed/NCBI
8	Chapman CJ, Healey GF, Murray A, et al: EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 33:1319–1326. 2012. View Article : Google Scholar : PubMed/NCBI
9	Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW and Robertson JF: Audit of the autoantibody test, Early CDT®-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer. 83:51–55. 2014. View Article : Google Scholar : PubMed/NCBI
10	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
11	Chapman C, Murray A, Chakrabarti J, et al: Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol. 18:868–873. 2007. View Article : Google Scholar : PubMed/NCBI
12	Piura E and Piura B: Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. J Oncol. 2011.9824252011.PubMed/NCBI
13	Hall M, Bates S and Peters G: Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene. 11:1581–1588. 1995.PubMed/NCBI
14	Baldi A, De Luca A, Esposito V, Campioni M, Spugnini EP and Citro G: Tumor suppressors and cell-cycle proteins in lung cancer. Pathology Res Int. 2011:6050422011. View Article : Google Scholar
15	Johnson JL, Pillai S and Chellappan SP: Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int. 2012:9404052012. View Article : Google Scholar : PubMed/NCBI
16	Matsushime H, Ewen ME, Strom DK, et al: Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell. 71:323–334. 1992. View Article : Google Scholar : PubMed/NCBI
17	Dickson MA: Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res. 20:3379–3383. 2014. View Article : Google Scholar : PubMed/NCBI
18	Looi K, Megliorino R, Shi FD, Peng XX, Chen Y and Zhang JY: Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep. 16:1105–1110. 2006.PubMed/NCBI
19	Ye H, Sun C, Ren P, et al: Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. Oncol Lett. 5:663–668. 2013.PubMed/NCBI
20	Ye L, Guan S, Zhang C, et al: Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma. Tumour Biol. 34:1873–1877. 2013. View Article : Google Scholar : PubMed/NCBI
21	Jin Y, Guan S, Liu L, Sun S, Lee KH and Wei J: Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer. Asian Pac J Clin Oncol. May 9–2014.(Epub ahead of print). View Article : Google Scholar
22	Zhang C, Ye L, Guan S, et al: Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. Tumour Biol. 35:2047–2051. 2014. View Article : Google Scholar : PubMed/NCBI
23	Lee CT, Capodieci P, Osman I, et al: Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res. 5:977–983. 1999.PubMed/NCBI
24	Chen YT, Scanlan MJ, Sahin U, et al: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 94:1914–1918. 1997. View Article : Google Scholar : PubMed/NCBI
25	Kanda M, Matthaei H, Wu J, et al: Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 142:730–733.e9. 2012. View Article : Google Scholar : PubMed/NCBI